Faculty profile

Elena Elimova

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Elena Elimova

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
37 publications in the last five years, latest in 2026.
Senior (last) author on 11 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

155

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Clinical Trial Gastroesophageal Cancer Her 2 Positive

Latest papers

Risk prediction model for brain metastasis risk among patients diagnosed with primary gastrointestinal cancers.
British journal of cancer · 2026
Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
Vascular Resection for Pancreas Cancer: Ten Years Experience From a Single High-volume Center.
Annals of surgery · 2026

All 52 publications

Latest funding

A randomized phase II study of ramucirumab and paclitaxel +/- zanidatamab in HER2 overexpressing advanced gastroesophageal adenocarcinoma
CIHR · 2022 · Nominated PI
$748,990
A randomized phase II study of ramucirumab and paclitaxel +/- zanidatamab in HER2 overexpressing advanced gastroesophageal adenocarcinoma
CIHR · 2022 · Nominated PI
$2,995,962

All 2 grants and awards

52 publications.

Risk prediction model for brain metastasis risk among patients diagnosed with primary gastrointestinal cancers.

Barcelona MVN, Kataki KJ, Rahman FA, Moraes FY, Millar BA, Conrad T, Keilty D, Hope A, Sun A, Kongkham P, Elimova E, Deng Y, Shultz D, Yan M

British journal of cancer2026

DOI: 10.1038/s41416-026-03587-8 PMID: 42649380

Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies.

Lee KW, Elimova E, Oh DY, Beeram M, Doi T, Yeung KT, Samuel Nached T, Shah KV, Fuller DS, Shpektor D, Loro E, Meric-Bernstam F

Clinical cancer research : an official journal of the American Association for Cancer Research2026

DOI: 10.1158/1078-0432.ccr-25-4158 PMID: 41870284

Vascular Resection for Pancreas Cancer: Ten Years Experience From a Single High-volume Center.

Henault D, Kunde H, Zatzman C, Bevacqua D, Arshinoff DLA, Cleary SP, Dawson LA, Elimova E, Grant R, Hosni A, Jang RW, Knox JJ, Mesci A, Moore M, Moulton CE, Reichman TW, Shwaartz C, Tsang ES, McGilvray ID, Gallinger S

Annals of surgery2026

DOI: 10.1097/sla.0000000000006567 PMID: 39417806

Association Between Pre-Diagnostic Delay and Survival Among Patients With Esophageal and Gastric Cancer Treated With Curative Intent During the COVID19 Pandemic.

Wang X, Bach Y, Lajkosz K, Espin-Garcia O, Aoyama H, Wang M, McLaughlin R, Ma L, Barron C, Rehman FA, Chen EX, Yeung JC, Swallow CJ, Brar S, Wong R, Mesci A, Kim J, Veit-Haibach P, Kalimuthu S, Jang RW, Elimova E

Cancer medicine2025Senior author

DOI: 10.1002/cam4.70939 PMID: 40347058

Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.

Shitara K, Janjigian YY, Ajani J, Moehler M, Yao J, Wang X, Chhibber A, Pandya D, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli A, Liu T, Schenker M, Yañez P, Kowalyszyn R, Karamouzis M, Zander T, Feeney K, Elimova E, Doshi P, Li M, Lei M

Nature medicine2025

DOI: 10.1038/s41591-025-03575-0 PMID: 40055521

The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer.

Farooq AR, Zhang AX, Chan-Seng-Yue M, Topham JT, O'Kane GM, Jang GH, Fischer S, Dodd A, Holter S, Wilson J, Grant RC, Aung KL, Zogopoulos G, Elimova E, Prince R, Jang R, Moore M, Biagi J, Tang P, Goodwin R, Bathe OF, Marra M, Laskin J, Renouf DJ, Schaeffer DF, Karasinska JM, Notta F, Gallinger S, Knox JJ, Tsang ES

NPJ precision oncology2025

DOI: 10.1038/s41698-025-00888-8 PMID: 40185871

Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial.

Meric-Bernstam F, Rha SY, Hamilton E, Kang YK, Hanna DL, Iqbal S, Lee KW, Lee J, Beeram M, Oh DY, Chaves J, Goodwin RA, Ajani JA, Yang L, Oza R, Elimova E

Nature communications2025Senior author

DOI: 10.1038/s41467-025-59279-z PMID: 40341383

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.

Elimova E, Ajani J, Burris H, Denlinger CS, Iqbal S, Kang YK, Kim JH, Lee KW, Lin B, Mehta R, Oh DY, Rha SY, Seol YM, Yang L, Ozog MA, Garfin PM, Ku G

The Lancet. Oncology2025First author

DOI: 10.1016/s1470-2045(25)00287-6 PMID: 40473445

Ramucirumab and paclitaxel in second or greater lines of therapy in patients with HER2-positive gastroesophageal cancer: a single center study.

Bach Y, Sharma D, Aoyama H, Ma LX, Barron CC, Wang X, Akhtar S, Yang Y, St Bernard A, McLaughlin R, Megid TBC, Farooq AR, Chen EX, Jang RWJ, Elimova E

The oncologist2025Senior author

DOI: 10.1093/oncolo/oyaf037 PMID: 40152313

Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial

Knox JJ, Jang GH, Grant RC, Zhang A, Ma L, Elimova E, Jang R, Moore M, Biagi J, Tehfe M

Nature Communications202547 citations

DOI: 10.1038/s41467-025-60808-z

Something wrong or missing on this profile? Suggest a correction

Elena Elimova

Research

Latest papers

Latest funding

Risk prediction model for brain metastasis risk among patients diagnosed with primary gastrointestinal cancers.

Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies.

Vascular Resection for Pancreas Cancer: Ten Years Experience From a Single High-volume Center.

Association Between Pre-Diagnostic Delay and Survival Among Patients With Esophageal and Gastric Cancer Treated With Curative Intent During the COVID19 Pandemic.

Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.

The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer.

Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial.

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.

Ramucirumab and paclitaxel in second or greater lines of therapy in patients with HER2-positive gastroesophageal cancer: a single center study.

Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial

A randomized phase II study of ramucirumab and paclitaxel +/- zanidatamab in HER2 overexpressing advanced gastroesophageal adenocarcinoma

A randomized phase II study of ramucirumab and paclitaxel +/- zanidatamab in HER2 overexpressing advanced gastroesophageal adenocarcinoma

Frequent collaborators

Patrick Veit-Haibach

Jonathan Yeung

Osvaldo Espin Garcia

Steven Gallinger

Geoffrey Liu

John Kim

Robert Grant

Wei Xu

Divya Sharma

Andrew Hope

Ian Mcgilvray

Conrad Falkson

Faiyaz Notta

Erin Kennedy

Axel BENHAMED

Pierre-Gilles Blanchard

Eitan Amir

Anand Ghanekar

Gonzalo Sapisochin

Michael Verret

Manoj Lalu

Susan Brogly

Karineh Kazazian

Lawson Eng

Jordan Feld

Jennifer Flemming

Jennifer Flemming

Michael Yan

Timothy Whelan

Edward Passos

John Agzarian

Paul Engels

Ilun Yang

Dennis Hong

Bobby Shayegan

Shivani Dadwal

Maryam Monajemzadeh

Mark Norman Levine

Girish Kulkarni

Natalie Coburn